At Boreal, we are committed to improving cancer patient care through development of research tools and diagnostic tests based on monitoring of circulating tumor DNA in plasma.
Boreal’s OnTarget™ platform performs highly sensitive mutation detection to enable accurate tumor profiling and real-time monitoring of tumor evolution from cell-free DNA in plasma. The OnTarget™ assay is available as a research-use service to reveal tumor mutations that are undetectable with other methods and may help guide selection of therapy, improve clinical trial efficiency, and accelerate drug development programs.
Location: Canada, British Columbia, Electoral Area A
Member count: 11-50
Total raised: $18M
Founded date: 2007
Investors 3
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Illumina V... | illuminaVe... |
| - | In-Q-Tel | iqt.org |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 05.10.2013 | Series C | $18M | - | finsmes.co... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 25.06.2015 | Single-cel... | Single-cell technologies advan... | - | - | cambridgen... |
| 25.06.2015 | Single-cel... | Biologists are looking to extr... | - | - | cambridgen... |
| 07.10.2013 | Boreal Gen... | LOS ALTOS, CA, Privately hel... | - | - | vcnewsdail... |
| 05.10.2013 | Boreal Gen... | Boreal Genomics, a Los Altos, ... | funding S... | - | finsmes.co... |